ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab

DRUG2 trials

Sponsors

Second Affiliated Hospital of Guangzhou Medical University

Conditions

Hepatic CancerLung CancerNon-small Cell Lung CancerSurgery

Phase 2

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

RecruitingNCT06492421

Second Affiliated Hospital of Guangzhou Medical UniversityLung Cancer, Non-small Cell Lung Cancer, Surgery

Start: 2024-07-01End: 2035-12-30Target: 90Updated: 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

RecruitingNCT06492408

Second Affiliated Hospital of Guangzhou Medical UniversityHepatic Cancer, Surgery

Start: 2024-07-01End: 2033-12-30Target: 90Updated: 2024-07-09